Evotec ROA 2025

Mis teeb Evotec?

Evotec SE is a biotechnology company based in Hamburg that specializes in the development of drug compounds for the pharmaceutical and biotech industries. The company was founded in 1993 as part of a research project at the University of Hamburg and has since become one of the leading drug discovery and development companies globally. Evotec's business model is based on collaborating with its customers, primarily large pharmaceutical companies, to develop new and innovative drugs. Evotec offers its extensive expertise in drug discovery and acts as a service provider. The company has modern laboratories equipped with state-of-the-art scientific methods and technologies. Customers benefit from the scientists' years of experience and collaboration with renowned academic institutions worldwide. Evotec operates in the Discovery, Development, and Manufacturing segments, providing a wide range of services to its customers. In the Discovery segment, the focus is on identifying drug candidates and preclinical development of drugs using advanced technologies and research methods. In the Development segment, Evotec supports its customers in the planning, execution, and analysis of clinical trials. The close collaboration with customers allows Evotec's scientists to respond quickly and effectively to feedback and requirements. The Manufacturing segment involves the industrial production of drugs. Evotec offers a broad range of products, including both its own and customer-requested drug compounds. One example is the drug DiaPep277 for the treatment of Type 1 diabetes. DiaPep277 was developed by Evotec in collaboration with Israeli company Andromeda Biotech and is now distributed by Teva Pharmaceuticals. Another example is the drug EVT307, which was developed by Evotec in collaboration with pharmaceutical company Boehringer Ingelheim and is currently being tested in Phase II clinical trials for the treatment of schizophrenia. Evotec's success is also based on its expertise in the production of small molecules. Small molecules are drug compounds characterized by their small size and highly specific binding to target proteins. In contrast, the production of large molecules such as antibodies or biologics is more complex and expensive in development due to their size. Evotec's success story continues: In 2019, the company achieved record results, increasing its revenue by 23 percent to 446.4 million euros. The number of employees has also steadily grown in recent years and now exceeds 3,000 employees worldwide. Evotec is considered one of the most successful biotechnology companies in Europe today. Evotec ist eines der beliebtesten Unternehmen auf Eulerpool.com.